What kind of nephritis is sparsentan/sparsentan mainly used to treat?

Sparsentan is a new non-immunosuppressive single molecule drug mainly used to treat immunoglobulin A tubulointerstitial disease (IgA nephropathy, IgAN). IgAN is a chronic progressive kidney disease characterized by intraglomerular deposition of immunoglobulin A. The pathogenesis of this disease is complex and involves abnormal responses of the immune system as well as the influence of genetic and environmental factors, ultimately leading to a gradual decline in kidney function.

The clinical manifestations of IgAN include hematuria, proteinuria, hypertension, and kidney swelling. Over time, a patient's kidney function may worsen and eventually develop end-stage renal disease, requiring dialysis or a kidney transplant. Therefore, early diagnosis and effective treatment are particularly important. Traditionally, the treatment of IgAN mainly relies on immunosuppressants and blood pressure control drugs. However, these therapies are often accompanied by side effects, and the therapeutic effect varies depending on individual differences.

Sparsentan can effectively reduce the inflammatory response in the glomerulus, reduce proteinuria, and improve renal function by simultaneously antagonizing the endothelinA receptor (ETAR) and angiotensin II subtype 1 receptor (AT1R). Studies have shown that sparsentane not only effectively reduces urinary protein excretion, but also significantly improves the progression of kidney disease. It is particularly effective for patients with high blood pressure, one of the important risk factors for IgAN.

The innovation of sparsentan lies in its dual-targeting mechanism, which is the first of its kind in currentIgAN treatments. Compared with traditional single-target drugs, this dual mechanism of sparsentan gives it greater potential in controlling the condition and slowing down disease progression. In addition, sparsentan is relatively well tolerated and has fewer side effects, providing patients with a new treatment option.

References:https://newsroom.csl.com/2024-10-17-CSL-Vifor-and-Travere-Therapeutics-Announce-Swissmedic-approval-of-FILSPARI-R-sparsentan-for-the-treatment-of-IgA-Nephropathy